Shares of Theravance Biopharma Inc. (NASDAQ:TBPH) hit a new 52-week high during trading on Friday . The company traded as high as $25.16 and last traded at $25.14, with a volume of 123,571 shares trading hands. The stock had previously closed at $24.37.

TBPH has been the subject of a number of recent analyst reports. Leerink Swann increased their price target on shares of Theravance Biopharma to $29.00 and gave the company an “outperform” rating in a research note on Monday, June 20th. Guggenheim initiated coverage on shares of Theravance Biopharma in a research note on Monday, June 20th. They issued a “buy” rating and a $30.00 price target for the company. Zacks Investment Research upgraded shares of Theravance Biopharma from a “hold” rating to a “buy” rating and set a $26.00 price target for the company in a research note on Tuesday, July 12th. Finally, Bank of America Corp. cut shares of Theravance Biopharma from a “buy” rating to a “neutral” rating in a research note on Thursday, May 5th. Three equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the company. The stock has a consensus rating of “Buy” and a consensus target price of $24.75.

The stock has a 50 day moving average price of $23.00 and a 200-day moving average price of $19.81. The company’s market capitalization is $1.21 billion.

Theravance Biopharma (NASDAQ:TBPH) last announced its quarterly earnings results on Monday, May 9th. The biopharmaceutical company reported ($1.10) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.96) by $0.14. The business had revenue of $18.40 million for the quarter, compared to analyst estimates of $18.69 million. On average, equities analysts forecast that Theravance Biopharma Inc. will post ($4.24) earnings per share for the current year.

An institutional investor recently raised its position in Theravance Biopharma stock. OppenheimerFunds Inc. raised its position in shares of Theravance Biopharma Inc. (NASDAQ:TBPH) by 1.1% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,103,485 shares of the biopharmaceutical company’s stock after buying an additional 12,120 shares during the period. OppenheimerFunds Inc. owned about 2.92% of Theravance Biopharma worth $18,086,000 as of its most recent filing with the SEC.

Theravance Biopharma, Inc is a biopharmaceutical company. The Company is engaged in creating medicines that make a difference in the lives of patients suffering from serious illness. The Company operates in the segment of discovery (research), development and commercialization of human therapeutics. The Company’s pipeline of internally discovered product candidates includes medicines to address the unmet needs of patients being treated for serious conditions primarily in the acute care setting.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.